US8916588 — Methods for treatment of attention deficit hyperactivity disorder
Method of Use · Assigned to Ironshore Pharmaceuticals and Development Inc Cayman Island · Expires 2032-03-23 · 6y remaining
What this patent protects
This patent protects methods for treating attention deficit disorder or attention deficit hyperactivity disorder using delayed and controlled release formulations of active drug.
USPTO Abstract
Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2357 |
— | methylphenidate-hydrochloride |
U-2357 |
— | methylphenidate-hydrochloride |
U-2357 |
— | methylphenidate-hydrochloride |
U-2357 |
— | methylphenidate-hydrochloride |
U-2357 |
— | methylphenidate-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.